Conditions: Glaucoma, Angle-Closure
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.

Detailed description:

Arms:
arm 1: Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.

Interventions: intervention 1: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution intervention 2: latanoprost
Intervention descriptions: intervention 1: COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks. intervention 2: Latanoprost administered in the affected eye(s) as prescribed by physician.

Protocol document: